Drug-coated Balloon Catheter Market To Reach $2.3 Billion By 2033

Drug-coated Balloon Catheter Market Size Growth & Trends

The global drug-coated balloon catheter market size is expected to reach USD 2.3 billion by 2033, expanding at 8.3% from 2026 to 2033, according to a new report by Grand View Research, Inc. The drug-coated balloon catheters are also referred as drug-eluted balloon catheter which eliminate the risk of stent thrombosis, minimize the duration of dual antiplatelet therapy, and facilitate targeted drug distribution. A few of the key causes driving the market growth are a growing elderly population, rising cardiovascular disease prevalence, and an increase in minimally invasive surgical techniques. Major cardiovascular conditions that are common worldwide include coronary artery disease (CAD), arrhythmias, peripheral vascular disorder, as well as congenital heart problems. Drug-eluting balloon catheters are frequently used to treat these kinds of conditions. The need for minimally invasive processes is expected to rise, and technological advancements in drug-eluting balloon catheters are expected to contribute to this growth. The growing older population has had a substantial impact on market share. Older individuals are more vulnerable to chronic health problems, making them susceptible to diseases like peripheral and cardiovascular abnormalities. Drug-eluting/drug-coated balloon catheters can treat and resolve these problems. Drug-eluting balloon catheters are used by patients to treat coronary atherosclerosis and prevent restenosis. The aforementioned factors are therefore expected to increase consumer demand for drug-eluting balloon catheters.

The Australian Institute of Health and Welfare estimates that in May 2022, out of 11.8 million enrollments, 7.0% of hospitalizations had an ICU stay, and 3.8% involved cardiovascular disorders. Additionally, it is anticipated that rising healthcare spending and the aging population, which is more likely to develop cardiovascular illnesses, would support market expansion.

Additionally, it is anticipated that rising healthcare spending and the aging population, which is more likely to develop cardiovascular illnesses, would support market expansion. For instance, according to a research paper released in December 2021 by Elsevier, the overall reported rate of confirmed cardiovascular diseases (CVDs) was 29.4% for adults aged 45 and over. The prevalence rate rose with age, rising from 22% within the 45-54 age range to 38% in the 70-and-over age group, indicating that the elderly population has a greater risk of developing CVDs. Given that drug-eluting/drug-coated balloons are used to treat a variety of cardiovascular problems, their prevalence is predicted to increase demand for them and aid in the recovery of those who are affected.

 Request a free sample copy or view report summary: Drug-coated Balloon Catheter Market Report

Drug-coated Balloon Catheter Market Report Highlights

• By type, the peripheral DCB segment accounted for the largest revenue share of over 71.4% in 2025, driven by the increasing prevalence of peripheral artery disease (PAD) and rising adoption of minimally invasive endovascular therapies, particularly for femoropopliteal lesions

• By end use, the hospitals segment accounted for the largest revenue share of 68.3% in 2025. The market is expanding due to more individuals choosing to have their medical care from expert surgeons in hospitals. Additionally, more hospitals are being built in emerging areas due to rising healthcare costs. Thus, it will propel the segment's growth

• North America held the largest share in 2025. This is mostly due to the presence of major market participants, the rising cost of healthcare in the U.S., and others, which are driving up the market across the region

• The Asia Pacific is expected to grow at the fastest rate during the forecast period. This is due growing aging population in nations like China and Japan and rising disposable income, rising awareness, and others.

Drug-coated Balloon Catheter Market Segmentation

Grand View Research has segmented the global drug-coated balloon catheter market based on type, end use, and region:

Drug-coated Balloon Catheter Type Outlook (Unit Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• Coronary DCB

  • By Indication

    • In-Stent Restenosis (ISR)

    • De-novo coronary lesions

    • Complex / Adjunct Coronary Lesions

  • By Drug Type

    • Paclitaxel

    • Sirolimus

    • Others

• Peripheral DCB

  • By Indication

    • Femoropopliteal Artery Disease (PAD)

    • Below-the-Knee (BTK)

  • By Drug Type

    • Paclitaxel

    • Sirolimus

    • Others

Drug-coated Balloon Catheter End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospitals

• Specialty Cardiac/Vascular Centers

• Ambulatory Surgical Centers (ASCs)

Drug-coated Balloon Catheter Regional Outlook (Unit Volume, Thousand Units; Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

  • Indonesia

  • Malaysia

  • Vietnam

• Latin America

  • Brazil

  • Argentina

  • Colombia

  • Chile

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Drug-coated Balloon Catheter Market

• Boston Scientific Corporation

• Medtronic

• B. Braun SE

• Concept Medical

• Abbott

• Koninklijke Philips N.V.

• Teleflex Incorporated (BIOTRONIK)

• Translumina

• MicroPort Scientific Corporation

• Cardionovum GmbH

• iVascular S.L.U.

• Lepu Medical

• Meril Life Sciences Pvt. Ltd.

• Cordis

• Acotec Scientific (Acotec / Acotec Scientific AG)

• SMT